A/DT proposed/VBN conflict-of-interest/NN policy/NN for/IN federally/RB funded/VBN biomedical/JJ researchers/NNS may/MD thwart/VB many/JJ high-technology/NN new/JJ ventures/NNS ,/, say/VBP 0/-NONE- *T*-1/-NONE- financiers/NNS ,/, researchers/NNS and/CC university/NN administrators/NNS ./.
The/DT National/NNP Institutes/NNPS of/IN Health/NNP policy/NN would/MD require/VB researchers/NNS to/TO cut/VB financial/JJ ties/NNS with/IN health-care/JJ businesses/NNS --/: or/CC lose/VB their/PRP$ government/NN money/NN ./.
Among/IN other/JJ concerns/NNS ,/, the/DT agency/NN says/VBZ 0/-NONE- researchers/NNS with/IN business/NN ties/NNS are/VBP more/RBR likely/JJ *-1/-NONE- to/TO falsify/VB findings/NNS in/IN order/NN *-2/-NONE- to/TO tout/VB new/JJ drugs/NNS ./.
As/IN ties/NNS between/IN academia/NN and/CC venture/NN capital/NN have/VBP blossomed/VBN in/IN recent/JJ years/NNS ,/, governmental/JJ fear/NN of/IN abuse/NN has/VBZ risen/VBN ./.
But/CC the/DT guidelines/NNS could/MD ``/`` make/VB it/PRP *EXP*-2/-NONE- impossible/JJ */-NONE- to/TO commercialize/VB research/NN ,/, ''/'' says/VBZ 0/-NONE- *T*-1/-NONE- Kenneth/NNP Smith/NNP ,/, associate/JJ provost/NN and/CC vice/NN president/NN for/IN research/NN at/IN Massachusetts/NNP Institute/NNP of/IN Technology/NNP ./.
The/DT NIH/NNP is/VBZ asking/VBG grant/NN recipients/NNS and/CC others/NNS for/IN comments/NNS on/IN the/DT proposed/VBN guidelines/NNS until/IN Dec./NNP 15/CD ./.
After/IN that/DT ,/, it/PRP will/MD make/VB a/DT final/JJ decision/NN on/IN the/DT policy/NN ./.
The/DT guidelines/NNS could/MD foil/VB future/JJ arrangements/NNS similar/JJ to/TO the/DT deal/NN behind/IN Lithox/NNP Inc./NNP ,/, a/DT Salem/NNP ,/, Mass./NNP ,/, start-up/NN ,/, says/VBZ 0/-NONE- *T*-1/-NONE- Robert/NNP Daly/NNP ,/, a/DT managing/VBG partner/NN of/IN TA/NNP Associates/NNPS ,/, a/DT venture-capital/JJ firm/NN ./.
With/IN $/$ 2.3/CD million/CD *U*/-NONE- ,/, he/PRP and/CC other/JJ investors/NNS launched/VBD Lithox/NNP last/JJ year/NN *-1/-NONE- to/TO market/NN a/DT gallstone/NN cure/NN being/NN developed/VBN */-NONE- by/IN researchers/NNS of/IN the/DT University/NNP of/IN California/NNP at/IN San/NNP Diego/NNP ./.
The/DT researchers/NNS ,/, who/WP *T*-2/-NONE- are/VBP being/VBG financed/VBN *-1/-NONE- by/IN the/DT Lithox/NNP funds/NNS ,/, will/MD receive/VB a/DT royalty/NN ,/, or/CC percentage/NN of/IN sales/NNS ,/, if/IN their/PRP$ research/NN yields/VBZ a/DT commercial/JJ product/NN ./.
But/CC because/IN the/DT University/NNP of/IN California/NNP ,/, like/IN many/JJ other/JJ universities/NNS ,/, shares/VBZ its/PRP$ royalties/NNS with/IN researchers/NNS ,/, it/PRP may/MD disqualify/VB itself/PRP from/IN federal/JJ funds/NNS under/IN the/DT proposed/VBN guidelines/NNS ,/, Mr./NNP Daly/NNP says/VBZ 0/-NONE- *T*-1/-NONE- ./.
The/DT high-tech/JJ industry/NN is/VBZ full/JJ of/IN the/DT kind/NN of/IN arrangement/NN that/IN the/DT new/JJ guidelines/NNS would/MD affect/VB *T*-1/-NONE- ./.
For/IN instance/NN ,/, Commonwealth/NNP BioVentures/NNP Inc./NNP ,/, a/DT venture-capital/JJ concern/NN ,/, last/JJ month/NN invested/VBD $/$ 600,000/CD *U*/-NONE- *-2/-NONE- to/TO launch/VB Amira/NNP Inc./NNP ,/, a/DT Worcester/NNP ,/, Mass./NNP ,/, concern/NN that/WDT *T*-1/-NONE- will/MD produce/VB pharmaceuticals/NNS ./.
Scientists/NNS Rima/NNP Kaddurah-Daouk/NNP and/CC Paul/NNP Schimmel/NNP conducted/VBD the/DT initial/JJ research/NN at/IN the/DT Massachusetts/NNP Institute/NNP of/IN Technology/NNP ./.
While/IN Ms./NNP Kaddurah-Daouk/NNP left/VBD MIT/NNP *-2/-NONE- to/TO head/VB Amira/NNP ,/, Prof./NNP Schimmel/NNP will/MD continue/VB *-1/-NONE- to/TO work/VB at/IN MIT/NNP ,/, serve/VB on/IN Amira/NNP 's/POS board/NN and/CC own/VB a/DT small/JJ equity/NN stake/NN in/IN the/DT company/NN ./.
The/DT Amira/NNP transaction/NN is/VBZ typical/JJ of/IN the/DT way/NN 0/-NONE- venture-capital/JJ firms/NNS are/VBP approaching/VBG the/DT task/NN of/IN */-NONE- commercializing/VBG biotechnology/NN research/NN *T*-1/-NONE- ./.
While/IN universities/NNS develop/VBP the/DT basic/JJ research/NN ,/, ``/`` venture/NN capitalists/NNS are/VBP the/DT ones/NNS best/RB positioned/VBD */-NONE- to/TO finance/VB its/PRP$ commercialization/NN ,/, ''/'' says/VBZ *T*-1/-NONE- Gloria/NNP W./NNP Doubleday/NNP of/IN Commonwealth/NNP ./.
``/`` This/DT is/VBZ the/DT best/JJS way/NN 0/-NONE- */-NONE- to/TO transfer/VB technology/NN straight/RB off/IN the/DT campuses/NNS of/IN universities/NNS *T*-1/-NONE- ./. ''/''
But/CC the/DT new/JJ guidelines/NNS could/MD prevent/VB scientists/NNS like/IN Prof./NNP Schimmel/NNP from/IN *-3/-NONE- being/VBG involved/VBN *-1/-NONE- with/IN start-ups/NNS such/JJ as/IN Amira/NNP ,/, venture/NN capitalists/NNS point/VBP out/RP 0/-NONE- *T*-2/-NONE- ./.
And/CC if/IN that/DT happens/VBZ ,/, the/DT entire/JJ process/NN of/IN */-NONE- transferring/VBG technology/NN to/TO the/DT marketplace/NN could/MD be/VB harmed/VBN *-1/-NONE- ,/, they/PRP say/VBP 0/-NONE- *T*-2/-NONE- ./.
The/DT stakes/NNS in/IN the/DT controversy/NN are/VBP large/JJ ./.
Last/JJ year/NN ,/, venture/NN capitalists/NNS spent/VBD an/DT estimated/VBN $/$ 600/CD million/CD *U*/-NONE- *-1/-NONE- to/TO finance/VB start-up/JJ companies/NNS in/IN medical/JJ and/CC biotechnology/NN businesses/NNS ,/, according/VBG to/TO the/DT National/NNP Venture/NNP Capital/NNP Association/NNP ,/, a/DT trade/NN group/NN ./.
Many/JJ of/IN the/DT deals/NNS involved/VBD transactions/NNS in/IN which/WDT scientific/JJ institutions/NNS or/CC researchers/NNS agreed/VBN *-2/-NONE- to/TO commercialize/VB their/PRP$ work/NN in/IN return/NN for/IN an/DT equity/NN stake/NN or/CC royalties/NNS *T*-1/-NONE- ./.
In/IN many/DT of/IN these/DT deals/VBZ ,/, ``/`` venture/NN capitalists/NNS had/VBD the/DT inside/NN track/NN ,/, ''/'' says/VBZ 0/-NONE- *T*-1/-NONE- Lawrence/NNP Bock/NNP of/IN Avalon/NNP Ventures/NNP ,/, La/NNP Jolla/NNP ,/, Calif/NNP ./.
Investors/NNS were/VBD willing/JJ *-1/-NONE- to/TO gamble/VB on/IN new/JJ technologies/NNS because/IN ``/`` we/PRP had/VBD exclusive/JJ rights/NNS to/TO those/DT technologies/NNS ,/, ''/'' he/PRP adds/VBZ 0/-NONE- *T*-2/-NONE- ./.
But/CC under/IN the/DT proposed/VBN guidelines/NNS ,/, all/DT federally/RB funded/VBN research/NN will/MD have/VB *-2/-NONE- to/TO be/VB reported/VBN *-1/-NONE- publicly/RB so/IN that/IN anyone/NN can/MD capitalize/VB on/IN the/DT work/NN ./.
``/`` Without/IN the/DT exclusivity/NN ,/, most/JJS venture/NN capitalists/NNS wo/MD n't/RB have/VB the/DT incentive/NN */-NONE- to/TO invest/VB in/IN such/JJ deals/NNS ,/, ''/'' Mr./NNP Bock/NNP says/VBZ *T*-1/-NONE- ./.
Last/JJ year/NN ,/, for/IN example/NN ,/, Avalon/NNP and/CC others/NNS invested/VBD $/$ 14/CD million/CD *U*/-NONE- in/IN Athena/NNP Neurosciences/NNP Inc./NNP ,/, South/NNP San/NNP Francisco/NNP ,/, Calif./NNP ,/, *-1/-NONE- to/TO license/VB and/CC develop/VB technology/NN for/IN delivery/NN of/IN drugs/NNS to/TO the/DT brain/NN ./.
But/CC before/IN Athena/NNP was/VBD able/JJ *-1/-NONE- to/TO get/VB an/DT exclusive/JJ license/NN to/TO the/DT technology/NN ,/, the/DT Federal/NNP Register/NNP published/VBD most/JJS of/IN the/DT details/NNS ,/, ``/`` */-NONE- giving/VBG all/DT of/IN the/DT company/NN 's/POS potential/JJ competitors/NNS a/DT chance/NN */-NONE- to/TO exploit/VB it/PRP ,/, ''/'' Mr./NNP Bock/NNP says/VBZ 0/-NONE- *T*-2/-NONE- ./.
Athena/NNP eventually/RB acquired/VBD exclusive/JJ rights/NNS to/TO the/DT technology/NN and/CC currently/RB is/VBZ developing/VBG it/PRP ./.
But/CC ,/, says/VBZ *ICH*-1/-NONE- Mr./NNP Bock/NNP ,/, ``/`` It/PRP was/VBD a/DT close/JJ call/NN ./. ''/''
The/DT proposed/VBN guidelines/NNS could/MD also/RB delay/VB commercialization/NN --/: and/CC force/VB small/JJ companies/NNS to/TO waste/VB scarce/JJ capital/NN ,/, entrepreneurs/NNS say/VBP 0/-NONE- *T*-1/-NONE- ./.
If/IN start-ups/NNS ca/MD n't/RB have/VB early/JJ access/NN to/TO research/NN being/NN conducted/VBN */-NONE- at/IN institutions/NNS ,/, ``/`` we/PRP have/VBP *-2/-NONE- to/TO replicate/VB it/PRP ourselves/PRP or/CC do/VB without/IN the/DT research/NN ,/, ''/'' says/VBZ 0/-NONE- *T*-1/-NONE- Ruth/NNP Emyanitoff/NNP ,/, manager/NN of/IN business/NN development/NN at/IN Applied/NNP bioTechnology/NNP Inc./NNP ,/, a/DT Cambridge/NNP ,/, Mass./NNP ,/, concern/NN ./.
*/-NONE- Duplicating/VBG research/NN is/VBZ both/DT costly/JJ and/CC time-consuming/JJ for/IN a/DT start-up/NN ,/, Ms./NNP Emyanitoff/NNP says/VBZ 0/-NONE- *T*-1/-NONE- ./.
For/IN its/PRP$ part/NN ,/, NIH/NNP insists/VBZ that/IN its/PRP$ guidelines/NNS ``/`` should/MD not/RB stifle/VB research/NN creativity/NN or/CC technology/NN transfer/NN from/IN the/DT research/NN laboratory/NN to/TO commercial/JJ use/NN ./. ''/''
Universities/NNS such/JJ as/IN Harvard/NNP and/CC MIT/NNP should/MD be/VB able/JJ *-2/-NONE- to/TO develop/VB a/DT way/NN 0/-NONE- */-NONE- to/TO act/VB as/IN brokers/NNS for/IN the/DT individual/JJ scientists/NNS *T*-3/-NONE- ,/, says/VBZ 0/-NONE- *T*-4/-NONE- Katherine/NNP Bick/NNP ,/, who/WP *T*-1/-NONE- oversees/VBZ the/DT huge/JJ NIH/NNP grants/NNS program/NN as/IN its/PRP$ deputy/NN director/NN for/IN extramural/JJ research/NN ./.
NIH/NNP staff/NN members/NNS believe/VBP 0/-NONE- the/DT guidelines/NNS are/VBP essential/JJ *-2/-NONE- to/TO prevent/VB the/DT escalation/NN of/IN problems/NNS that/WDT *T*-1/-NONE- have/VBP already/RB begun/VBN *-3/-NONE- to/TO surface/VB in/IN scientific/JJ ventures/NNS ./.
Not/RB long/RB ago/RB ,/, scientists/NNS holding/VBG stock/NN in/IN Spectra/NNP Pharmaceutical/NNP Services/NNPS Inc./NNP were/VBD accused/VBN *-1/-NONE- of/IN *-2/-NONE- falsifying/VBG research/NN *-3/-NONE- to/TO boost/VB the/DT stock/NN ./.
Many/JJ officials/NNS are/VBP also/RB concerned/VBN about/IN companies/NNS getting/VBG a/DT ``/`` free/JJ ride/NN ''/'' on/IN government-sponsored/JJ research/NN ./.
A/DT congressional/JJ subcommitee/NN has/VBZ been/VBN investigating/VBG the/DT potential/JJ abuse/NN from/IN researchers/NNS holding/VBG stock/NN in/IN companies/NNS exploiting/VBG their/PRP$ research/NN ./.
Among/IN other/JJ provisions/NNS ,/, the/DT NIH/NNP guidelines/NNS would/MD prohibit/VB researchers/NNS and/CC members/NNS of/IN their/PRP$ immediate/JJ families/NNS from/IN *-3/-NONE- holding/VBG stock/NN in/IN any/DT company/NN that/WDT *T*-2/-NONE- is/VBZ affected/VBN *-1/-NONE- by/IN the/DT outcome/NN of/IN their/PRP$ research/NN ./.
Ms./NNP Bick/NNP ,/, the/DT NIH/NNP administrator/NN ,/, says/VBZ 0/-NONE- the/DT business/NN and/CC scientific/JJ community/NN is/VBZ overreacting/VBG to/TO what/WP the/DT agency/NN merely/RB meant/VBD *T*-1/-NONE- to/TO be/VB ``/`` ideas/NNS for/IN discussion/NN ./. ''/''
The/DT predictions/NNS of/IN doom/NN are/VBP ``/`` premature/JJ ,/, ''/'' she/PRP says/VBZ 0/-NONE- *T*-1/-NONE- ./.
But/CC when/WRB agencies/NNS like/IN the/DT NIH/NNP circulate/VBP guidelines/NNS *T*-1/-NONE- ,/, they/PRP 've/VBP often/RB already/RB formulated/VBN policy/NN ,/, veteran/NN scientists/NNS say/VBP 0/-NONE- *T*-2/-NONE- ./.
Indeed/RB ,/, institutions/NNS already/RB are/VBP taking/VBG note/NN ./.
On/IN Sept./NNP 14/CD ,/, Harvard/NNP began/VBD *-2/-NONE- circulating/VBG a/DT conflict-of-interest/JJ policy/NN statement/NN that/IN ,/, in/IN effect/NN ,/, *T*-1/-NONE- would/MD follow/VB the/DT NIH/NNP guidelines/NNS faithfully/RB ./.
The/DT University/NNP of/IN California/NNP at/IN San/NNP Francisco/NNP is/VBZ also/RB circulating/VBG a/DT memo/NN *ICH*-1/-NONE- among/IN its/PRP$ scientific/JJ faculty/NN that/WDT *T*-2/-NONE- will/MD restrict/VB contact/NN with/IN the/DT world/NN of/IN business/NN ./.
In/IN many/JJ other/JJ institutions/NNS ,/, scientists/NNS are/VBP shunning/VBG contacts/NNS with/IN venture/NN investors/NNS until/IN the/DT NIH/NNP policy/NN is/VBZ settled/VBN *-1/-NONE- ./.
Says/VBZ *ICH*-1/-NONE- Mr./NNP Daly/NNP ,/, the/DT venture/NN capitalist/NN :/: ``/`` It/PRP *EXP*-2/-NONE- does/VBZ n't/RB matter/VB whether/IN they/PRP call/VBP it/PRP guidelines/NNS or/CC policy/NN ./.
The/DT damage/NN is/VBZ already/RB done/VBN *-1/-NONE- ./.

